Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end.
Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert.
Technical report: https://t.co/E7IHfkvvD3
Blog post: https://t.co/GfJAfzj0Qx
Apply for access: https://t.co/E0SR9znZiP
I am looking for an intern to do a research project on RL posttraining of LLMs. If you are PhD student and would like to work with me for several months pushing the efficiency of RL systems, send me an email with the [efficient_rl_internship] subject. Friends, please, retweet.
Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot.
Technical report: https://t.co/9uU6GQCdM7
Blog: https://t.co/TFyCzlZ4qN
Apply for access: [email protected]
5 months from Latent-X1 to Latent-X2. AI-generated antibodies with drug-like developability and low immunogenicity in human panels — zero-shot.
Available now for selected partners.
Today at 11am I’ll present some of the exciting work in AI x Bio we’ve been up to at @Latent_Labs at the @RenPhilanthropy booth (Hall A/B, booth 1343 @NeurIPSConf - straight through the entrance at the back left). Come say hi!
I'm so happy to share that I’ll be joining @UofT as an Assistant Professor of Statistical Sciences and Computer Science, with an appointment at the @VectorInst, in 2026!
I'm recruiting postdocs and PhD students: https://t.co/FWBh0BiDqP!
Please help me spread the word!
🧵(1/5)
Where are all the de novo designed therapeutics? In a guest post by @frdreyer, we break down what the actual bottlenecks, challenges, and opportunities are in building and deploying purely in silico drug discovery engines, with a focus on antibody structure.
Link below 👇
Introducing Latent-X — our all-atom frontier AI model for protein binder design.
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: https://t.co/NamdznPWjL
Blog: https://t.co/2UkYDEe8a9
Technical report: https://t.co/0m2s3y7vwN
@Latent_Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design.
Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can play - but not all are in a position to develop their own advanced models. That’s where @Latent_Labs comes in.
Computational design of developable therapeutic antibodies: efficient traversal of binder landscapes and rescue of escape mutations https://t.co/SvPyPO7FXB #biorxiv_bioinfo
My co-authors and I are pleased to share our latest work on paired antibody language models, where we trained the largest open-source antibody-specific models to date on over two billion sequences from the Observed Antibody Space.
We have released the weights, which can be accessed from our Hugging Face repo. We are grateful to NVIDIA for the compute resources. This was a great team effort by @frdreyer and myself, Charlotte Deane, Aleks Kovaltsuk, Dom Miketa, and @DrDouglasPires.
The DEGAS webinar series is back. The new season will begin on 6 Dec 3:00pm CET when @epomqo present "On the stability of spectral graph filters and beyond: A topological perspective". Check out https://t.co/PWFws3v6Zv for details. #graphsignalprocessing